Sign In
4 Mar 2013 15:23
4 March 2013
Holdings in Company: e-Therapeutics plc
e-Therapeutics plc (AIM: ETX) was notified on 1 March that following the completion of the share placings announced that day the resultant holdings of the Company's CEO Professor Malcolm Young were as shown below:
Number of ordinary shares | % of issued share capital | |
Direct beneficial interest | 20,644,958 | 7.84 |
Indirect interest* | 377,784 | 0.14 |
Total beneficial interest | 21,022,742 | 7.99 |
* Held through Professor Young's interest in Novotech Investment Limited and Novotech Syndicate LLP
-Ends-
Contacts:
e-Therapeutics plc
Daniel Elger
Tel: +44 (0) 7909 915 068
www.etherapeutics.co.uk
Panmure Gordon (UK) Limited
Corporate Finance: Fred Walsh / Grishma Patel
Corporate Broking: Hannah Woodley
Tel: +44 (0) 20 7886 2500
www.panmure.com
ETX.L (ETX)
Follow the stocks
